Then, in 2017, a study reported that GSTP1 was involved in anxiety and depression behaviors in 10-month-old triple transgenic mice of AD, and melatonin could serve as a potential candidate drug to improve the neuropsychiatric behaviors in AD via modulating the expression of the GSTP1 [36]. Here, GSTP1 is linked to major depressive disorder.